| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Pier Mannuccio Mannucci | Q69358288 |
| P2093 | author name string | Meyer D | |
| Rodeghiero F | |||
| Berntorp E | |||
| Srivastava A | |||
| Ginsburg D | |||
| Sadler JE | |||
| Peake I | |||
| Boulyjenkov V | |||
| Bochkov N | |||
| P433 | issue | 2 | |
| P304 | page(s) | 160-174 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Thrombosis and Haemostasis | Q15724413 |
| P1476 | title | Impact, diagnosis and treatment of von Willebrand disease | |
| P478 | volume | 84 |
| Q34909055 | A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease |
| Q33917215 | A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice |
| Q43974340 | Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces |
| Q35848737 | Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. |
| Q37545150 | BLOC-2 subunit HPS6 deficiency affects the tubulation and secretion of von Willebrand factor from mouse endothelial cells. |
| Q36369902 | Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease |
| Q30535420 | Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes |
| Q34873778 | Clinical utility gene card for: von Willebrand disease |
| Q34022444 | Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor |
| Q55617050 | Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. |
| Q37088945 | Complications of hysterectomy in women with von Willebrand disease |
| Q37324147 | De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD. |
| Q35220634 | Diagnostic approach to von Willebrand disease |
| Q34463716 | Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery |
| Q88271396 | Effects of plasma glycosyltransferase on the ABO(H) blood group antigens of human von Willebrand factor |
| Q33401369 | Endothelial cells and thrombotic microangiopathy |
| Q47416217 | Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels |
| Q64077886 | Evaluation of blood type as a potential risk factor for early postpartum hemorrhage |
| Q34160799 | Functional architecture of Weibel-Palade bodies |
| Q79768905 | Heart rate variability, hemostatic and acute inflammatory blood parameters in healthy adults after short-term exposure to welding fume |
| Q89722194 | Hemophilia therapy: the future has begun |
| Q93196766 | How I manage severe von Willebrand disease |
| Q89287175 | Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States |
| Q35995241 | Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage |
| Q51566372 | Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF. |
| Q90307753 | One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients |
| Q38794900 | Perioperative bleeding and thrombotic risks in patients with Von Willebrand disease. |
| Q37077021 | Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial |
| Q85651166 | Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A |
| Q28552945 | Postpartum Hemorrhage in Women with Von Willebrand Disease - A Retrospective Observational Study |
| Q37609352 | Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells |
| Q34282379 | Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. |
| Q37043558 | The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels |
| Q38880592 | The clinical value of von Willebrand factor in colorectal carcinomas. |
| Q37479585 | The diagnosis and treatment of von Willebrand disease in children |
| Q37193881 | The molecular genetics of von Willebrand disease |
| Q33896726 | The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF. |
| Q34207741 | The use of desmopressin in acquired haemophilia A: a systematic review |
| Q36357598 | Utility of a Paediatric Bleeding Questionnaire as a screening tool for von Willebrand disease in apparently healthy children |
| Q35849223 | VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population |
| Q37253917 | Von Willebrand disease in the United States: a perspective from Wisconsin |
| Q58781583 | Von Willebrand disease in the elderly: clinical perspectives |
| Q28742241 | Von Willebrand disease: an overview |
| Q83672337 | [The significance of bleeding disorders in patients with epistaxis] |
| Q55053921 | von Willebrand disease. |
| Q91959533 | von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD |
Search more.